According to the quoted source, in the first quarter of 2022, BioNTech’s revenues more than tripled, reaching 6.37 billion euros, while the net profit rose to 3.70 billion euros.
“As a result of the increase in orders placed at the end of 2021, following the expansion of the Omicron variant, we started the year 2022 with solid results, being well positioned to meet our annual financial goals,” said Chief Financial Officer Jens Holstein, informs Agerpres.
In 2022, BioNTech expects vaccine sales of between € 13 billion and € 17 billion, down from € 19 billion last year.
The estimates of BioNTech, based in Mainz, near Frankfurt, are based on company orders, which have remained at about 2.4 billion doses, below the level of 2.6 billion doses delivered in 2021.
Rivala Moderna expects higher vaccine sales in the second half of 2022 than in the previous six months,
The Pfizer-BioNTech vaccination campaign, marketed under the name Comirnaty, began in December 2020. It was the first vaccine based on mRNA technology approved by regulators as well as the best-selling drug in the world in 2021.
BioNTech recently announced that it will use the profits to develop other drugs, against cancer and other diseases, and plans to double its R&D spending by 1.4 to 1.5 billion euros in 2022.
If you like this article, we look forward to joining the community of readers on our Facebook page, with a Like below: